Welcome to our dedicated page for Nervgen Pharma SEC filings (Ticker: NGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page is intended to provide access to NervGen Pharma Corp. (NGEN) regulatory filings and related disclosures, alongside AI-generated summaries that help explain their contents in clear language. While no SEC filings are listed in the current data, NervGen’s public statements outline the clinical and regulatory context in which future filings would be prepared.
NervGen describes itself as a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. Its lead candidate, NVG-291, is a subcutaneously administered neuroreparative peptide evaluated in the Phase 1b/2a CONNECT SCI Study in individuals with chronic SCI, with ongoing enrollment in subacute SCI and preparation for a Phase 3 trial in chronic SCI.
According to the company, NVG-291 has received Fast Track designation from the U.S. Food and Drug Administration (FDA) and Orphan Drug designation from the European Medicines Agency (EMA) for the treatment of spinal cord injury. NervGen also references regulatory meetings with the FDA, including a Type C meeting and a planned End-of-Phase 2 meeting to align on the development and registration pathway for NVG-291.
As SEC filings such as annual reports (Form 10-K), quarterly reports (Form 10-Q) or current reports (Form 8-K) become available, this page can surface them with AI-powered highlights of key sections, such as clinical development updates for NVG-291 and NVG-300, risk factor discussions related to neuroreparative drug development, and disclosures around regulatory designations and trial status. AI summaries can assist readers in navigating lengthy documents by pointing to passages that discuss NervGen’s spinal cord injury focus, neurotraumatic and neurologic indications, and the company’s stated mission to enable nervous system repair.
NervGen Pharma Corp. appointed Keith Vendola, MD, MBA as Chief Financial Officer, effective immediately. Under his employment agreement, he will receive an annual base salary of $515,000 and be eligible for an annual cash bonus of up to 40% of salary, subject to Board discretion.
As part of his package, the Board granted Dr. Vendola options to purchase 812,002 common shares at an exercise price of $3.92 per share, vesting in three equal annual installments over three years and expiring ten years after grant. These options were issued under NervGen’s new 2026 Equity Incentive Plan.
At the recent annual meeting, shareholders approved an amendment to the Company’s Articles and adopted the 2026 Equity Incentive Plan, alongside amendments to the existing stock option plan and the routine re-appointment of KPMG as auditor and election of eight directors. The 6-K and key exhibits are incorporated by reference into NervGen’s Form F-10 shelf registration.
NervGen Pharma Corp. files its Annual Report on Form 40-F for the fiscal year ended December 31, 2025. The filing lists 79,649,257 Common Shares outstanding, incorporates an Annual Information Form, audited consolidated financial statements for 2025 and 2024, MD&A, and certifications via listed exhibits. The registry signature is dated March 31, 2026.
NervGen Pharma plans to voluntarily delist its common shares from the TSX Venture Exchange at the close of markets on March 16, 2026. The shares will continue trading on the Nasdaq Capital Market under the symbol NGEN, so investors will still be able to buy and sell the stock.
The company describes this as a strategic step as it moves into late-stage development for NVG-291, aiming to eliminate duplicative exchange fees and reduce legal, accounting, and regulatory complexity. Management expects this to free time and resources for clinical execution and long-term shareholder value goals.
In connection with the delisting, NervGen terminated its at-the-market equity program launched in December 2025. From January 1 through March 12, 2026, it issued 245 common shares under the program at a weighted average price of $6.20 per share, raising net proceeds of $1,489.
NervGen Pharma Corp. reported a planned leadership change in its finance function. Chief Financial Officer and Secretary William J. Adams, who also serves as Principal Financial and Accounting Officer, has resigned due to his retirement, effective March 15, 2026. The company states that his resignation is not related to any disagreement with management or the board.
Adams will provide transitional services through June 15, 2026 and will receive one-third of his current base salary during this period, along with an extension of the expiration date of his vested stock awards under existing equity award agreements. The board has appointed Dr. Adam Rogers as interim Chief Financial Officer and Principal Financial and Accounting Officer, effective on the same date Adams’ resignation becomes effective. This report is also incorporated by reference into NervGen’s existing Form F-10 registration statement.
NervGen Pharma Corp. has appointed Dr. Adam Rogers as its Chief Executive Officer and President, effective immediately, after he served as interim CEO and Board Chair. He will continue as Chairperson of the Board.
Under his new employment agreement with a U.S. subsidiary, Dr. Rogers will receive a $350,000 annual base salary and be eligible for an annual bonus of up to 30% of salary. He was granted options to purchase 717,891 common shares, split between options priced at $5.06 and $5.57 per share, vesting over four years. The Board also agreed to grant an additional 1,146,108 performance-based options, plus 37,784 fully vested shares and 617,135 performance-based restricted stock units, subject to equity plan approvals.
The agreement includes severance and change-of-control protections, providing salary continuation, COBRA benefits, bonus eligibility and equity vesting acceleration in certain terminations, with enhanced vesting if a qualifying termination occurs around a change of control.